XERS NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Xeris Pharmaceuticals Inc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 8.32 USD
-5.5% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 22.8% above the Trend Line and sits at 66.2% of its 52-week range. The latest completed week returned -5.5%, after a 8.2% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is volatility with 51/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 5d.

Setup score 63 out of 100
Latest Close 8.32 USD 24 Jul 2026
1W Return -5.5% latest completed week
4W Return 8.2% short-term follow-through
12W Return 32.5% quarterly tape
Trend Breadth 55.8% 29 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.5% Latest completed week; four-week move 8.2%. Indicator stack 38/80 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 58.29% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 51/100 conviction; expected move 16.5%. News sentiment 53/100 53 relevant articles in the latest sentiment read. Event risk 5d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 22.8% above the Trend Line and sits at 66.2% of its 52-week range. The latest completed week returned -5.5%, after a 8.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5012-week average 0.19

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership4/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.50Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 8.2% over four weeks, 32.5% over 12 weeks, and 65.7% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W-5.5%
4W8.2%
12W32.5%
26W11.8%
52W65.7%
Active trend streak2 weeks
Active weeks in one year29
Trend breadth55.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.46Latest activity-pressure read.
Pressure change47.7%Four-week change in activity pressure.
Leadership6.52Latest relative-leadership reading.
RS change343.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 88% Model confidence 84%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength48/100Blend of value, momentum, and quality. Underlying universe rank 53; rank 1 is best.
Value4/100Relative valuation strength. Underlying universe rank 97; rank 1 is best.
Quality97/100Profitability and accounting quality. Underlying universe rank 4; rank 1 is best.
Momentum89/100Medium-term price momentum. Underlying universe rank 12; rank 1 is best.
Growth85/100Revenue and earnings growth. Underlying universe rank 16; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework37/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
119.6x
Price divided by trailing earnings.
Price / sales
4.6x
Market value relative to trailing revenue.
EV / EBITDA
29.5x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
3.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
81.6%
Gross profit retained from each unit of revenue.
Operating margin
10.6%
Operating profit retained from revenue.
Free-cash-flow margin
15.8%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
41.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.7%
Net share repurchases relative to market value.
Shareholder yield
0.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

XERS shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.00, expected move of 16.5%, and Sharemaestro trend signal active.

Conviction51/100
Expected move16.5%
Put/call volume0.00
Pressure100
Speculation1
Volatility88
Trend agreement0
Open options detail
Insider activity13 / 7

13 acquisitions and 7 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment53/100

Weighted news tone is neutral across 53 relevant articles.

11 positive · 39 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings5dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move16.5%Nearest-chain priced movement where available.
52-week drawdown-17.5%Distance below the 52-week high.
13-week volatility4.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+11.9%Week of 3 Apr.
Worst week-7.4%Week of 27 Feb.
Latest week-5.5%Week of 24 Jul.

Shape of recent returns

Strong gains6
Modest gains5
Flat weeks0
Modest losses8
Sharp losses7
Recent vol4.8%13-week weekly-return volatility.
Base vol7.5%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew6.3% / -4.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape58/100

Trend, activity pressure, participation, and risk combine to a 58/100 tape read.

 Indicator analysis45/100

Latest 12-week confirmation: trend 2/12, activity pressure 10/12, relative leadership 4/12.

Activity pressure 0.50; No reversal markers Next-Week ExpectancyPositive 58.29%

Next-week expectancy is positive with a 58.29% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 33; Small Cap Core rank 98 SVQF37/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 467.0 of 746 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options35/100

XERS shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.00, expected move of 16.5%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 16.5% Sentiment53/100

Weighted news tone is neutral across 53 relevant articles.

Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates Insiders13 / 7

13 acquisitions and 7 disposals in the latest 180-day insider tape.

 Earnings5d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20268.32 USD-5.5%6.78 USD4.38 USD1.466.528.2MOn
17 Jul 20268.80 USD5.5%6.75 USD4.34 USD1.5511.487.3MOn
10 Jul 20268.34 USD0.7%6.70 USD4.30 USD1.431.8612.7MOff
3 Jul 20268.28 USD7.7%6.66 USD4.26 USD1.263.3611.3MOff
26 Jun 20267.69 USD10.6%6.60 USD4.22 USD0.99-2.6713.7MOff
19 Jun 20266.95 USD2.4%6.58 USD4.19 USD0.64-15.677.5MOff
12 Jun 20266.79 USD9.9%6.58 USD4.17 USD0.44-15.299.5MOff
5 Jun 20266.18 USD0.3%6.59 USD4.14 USD0.24-20.977.7MOff
29 May 20266.16 USD-0.5%6.63 USD4.12 USD0.28-24.765.5MOff
22 May 20266.19 USD-0.8%6.75 USD4.10 USD0.11-22.366.5MOff
15 May 20266.24 USD-4.4%6.85 USD4.08 USD-0.12-20.918.6MOff
8 May 20266.53 USD4.0%6.95 USD4.05 USD-0.39-17.5913.7MOff
1 May 20266.28 USD3.8%7.00 USD4.03 USD-0.82-16.545.4MOff
24 Apr 20266.05 USD-5.0%7.06 USD4.01 USD-0.93-18.417.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.